Literature DB >> 28833798

Expressions of programmed death (PD)-1 and PD-1 ligand (PD-L1) in cervical intraepithelial neoplasia and cervical squamous cell carcinomas are of prognostic value and associated with human papillomavirus status.

Wen Yang1, Yan-Ping Lu1, Yi-Zhou Yang1, Jia-Rui Kang2, Yi-Duo Jin2, Hong-Wei Wang2.   

Abstract

AIM: The programmed death 1/programmed death 1 ligand (PD-1/PD-L1) pathway can decrease the immune clearance effects of antigen-presenting cells and T lymphocytes to promote immune evasion of cervical cancer cells. However, the effects of this pathway on cervical intraepithelial neoplasia (CIN) progression and squamous cell carcinoma (SCC) metastasis are not clear. We herein investigated whether human papillomavirus infection could affect PD-1 and PD-L1 expression in CIN, and whether their expression is associated with CIN progression and SCC metastasis.
METHODS: We collected paraffin-embedded samples from two cohorts of patients: (i) CIN samples from cohort I (40 women who tested positive or negative for high-risk human papillomavirus [HR-HPV] with grades 0, I, and II-III CIN); and (ii) paired primary and metastatic tumor samples from cohort II (20 SCC patients with or without metastasis). Immunohistochemistry was used to detect expressions of PD-L1 in tumor cells and PD-1 in tumor-associated macrophages and tumor-infiltrating lymphocytes. We also measured P16INK4a expression and interferon-γ levels in the cervical tissues.
RESULTS: The most common HPV type seen in both cohorts of patients was HPV16, followed by HPV18. Increase in PD-L1 and PD-1 expression was positively correlated with HPV-positivity, increase in CIN grade, and tumor metastasis. Furthermore, upregulation of the PD-1/PD-L1 pathway was associated with decreased expression of the pro-inflammatory cytokine, interferon-γ and increased expression of P16INK4a .
CONCLUSION: Expression of PD-L1 and PD-1 could be used as clinical prognostic biomarkers for evaluating CIN and cervical cancer because of its positive correlation with CIN progression and tumor metastasis.
© 2017 Japan Society of Obstetrics and Gynecology.

Entities:  

Keywords:  cervical carcinoma; cervical intraepithelial neoplasia; human papillomavirus; programmed death 1; programmed death 1 ligand

Mesh:

Substances:

Year:  2017        PMID: 28833798     DOI: 10.1111/jog.13411

Source DB:  PubMed          Journal:  J Obstet Gynaecol Res        ISSN: 1341-8076            Impact factor:   1.730


  24 in total

1.  PD-1/PD-L1 immune checkpoint inhibitors in advanced cervical cancer.

Authors:  Ozlen Saglam; Jose Conejo-Garcia
Journal:  Integr Cancer Sci Ther       Date:  2018-04-14

2.  CD274 (PD-L1), CDKN2A (p16), TP53, and EGFR immunohistochemical profile in primary, recurrent and metastatic vulvar cancer.

Authors:  Sofia Lérias; Susana Esteves; Fernanda Silva; Mário Cunha; Daniela Cochicho; Luís Martins; Ana Félix
Journal:  Mod Pathol       Date:  2019-12-16       Impact factor: 7.842

Review 3.  Novel Therapeutics for Recurrent Cervical Cancer: Moving Towards Personalized Therapy.

Authors:  Alexander C Cohen; Brandon M Roane; Charles A Leath
Journal:  Drugs       Date:  2020-02       Impact factor: 9.546

4.  Tumor-Associated CD163+ M2 Macrophage Infiltration is Highly Associated with PD-L1 Expression in Cervical Cancer.

Authors:  Fan Guo; Yang-Chun Feng; Gang Zhao; Ran Zhang; Zhen-Zhen Cheng; Wei-Na Kong; Hui-Li Wu; Bin Xu; Xiang Lv; Xiu-Min Ma
Journal:  Cancer Manag Res       Date:  2020-07-15       Impact factor: 3.989

5.  Response to Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer: The Role of Immune-related Factors.

Authors:  Innocenza Palaia; Federica Tomao; Anna DI Pinto; Angelina Pernazza; Giusi Santangelo; Nicoletta D'Alessandris; Lucia Manganaro; Antonio Arno; Violante DI Donato; Giorgia Perniola; Carlo Della Rocca; Pierluigi Benedetti Panici
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

6.  PD-L1 Expression Correlates With Young Age and CD8+ TIL Density in Poorly Differentiated Cervical Squamous Cell Carcinoma.

Authors:  Ozlen Saglam; Junmin Zhou; Xuefeng Wang; Jose R Conejo-Garcia
Journal:  Int J Gynecol Pathol       Date:  2020-09       Impact factor: 3.326

7.  Immune checkpoint expression on peripheral cytotoxic lymphocytes in cervical cancer patients: moving beyond the PD-1/PD-L1 axis.

Authors:  F Solorzano-Ibarra; A G Alejandre-Gonzalez; P C Ortiz-Lazareno; B E Bastidas-Ramirez; A Zepeda-Moreno; M C Tellez-Bañuelos; N Banu; O J Carrillo-Garibaldi; A Chavira-Alvarado; M R Bueno-Topete; S Del Toro-Arreola; J Haramati
Journal:  Clin Exp Immunol       Date:  2021-01-18       Impact factor: 5.732

8.  CALLA: Efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter study.

Authors:  Jyoti Mayadev; Ana T Nunes; Mary Li; Michelle Marcovitz; Mark C Lanasa; Bradley J Monk
Journal:  Int J Gynecol Cancer       Date:  2020-05-23       Impact factor: 3.437

9.  'DURVIT': a phase-I trial of single low-dose durvalumab (Medi4736) IntraTumourally injected in cervical cancer: safety, toxicity and effect on the primary tumour- and lymph node microenvironment.

Authors:  J Rotman; C H Mom; E S Jordanova; T D de Gruijl; G G Kenter
Journal:  BMC Cancer       Date:  2018-09-12       Impact factor: 4.430

10.  Increased PD-1 Level in Severe Cervical Injury Is Associated With the Rare Programmed Cell Death 1 (PDCD1) rs36084323 A Allele in a Dominant Model.

Authors:  Mauro César da Silva; Fernanda Silva Medeiros; Neila Caroline Henrique da Silva; Larissa Albuquerque Paiva; Fabiana Oliveira Dos Santos Gomes; Matheus Costa E Silva; Thailany Thays Gomes; Christina Alves Peixoto; Maria Carolina Valença Rygaard; Maria Luiza Bezerra Menezes; Stefan Welkovic; Eduardo Antônio Donadi; Norma Lucena-Silva
Journal:  Front Cell Infect Microbiol       Date:  2021-07-01       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.